(A) Migration assay data for single agent lenalidomide, sorafenib and combination treated HUVEC reveals a dose response curve that has significant inhibition at all concentrations. Treatment of HUVEC with a 1:1 combination of lenalidomide and sorafenib showed superior inhibitive efficacy than monotherapy with either compound. There was no detectable difference between lenalidomide or sorafenib monotherapy for the migration assay. Each experimental condition was repeated six times. (B) Tube formation assay showed inhibition of HUVEC ability to form tubes with a maximal inhibition with lenalidomide treatment at 0.001 uM (p = 0.005). The tube formation capabilities of HUVEC were more profoundly inhibited by sorafenib than lenalidomide at all tested concentrations. The combination of compounds showed superior inhibitory efficacy at all concentrations. Each experimental condition was repeated four times. (C) Lenalidomide inhibited the rat aortic ring assay more effectively at lower concentrations than did sorafenib, and its inhibition was present at across all concentrations. Combination treatment with both compounds was more effective at all evaluable concentrations. Images are representative of those used for data derivation. Each experimental condition was repeated eight times.